Drilling Down

Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.

Improving patient monitoring through care-at-home services could help reduce maternal mortality, they say.

Brexafemme is a non-azole oral antifungal now approved to both treat and prevent recurrent yeast infections in women.

If approved, Perrigo’s Opill could be the first-ever nonprescription birth control pill.

The approval had been delayed as the regulatory agency reviewed data on Myfembree's impact on bone mineral density.